Fauci says pause on J&J COVID-19 shot should not prompt vaccine hesitancy
Reuters
Published Apr 14, 2021 11:59AM ET
Updated Apr 14, 2021 02:35PM ET
By Carl O'Donnell and Jarrett Renshaw
(Reuters) - Top U.S. health officials urged Americans to get vaccinated against COVID-19 on Wednesday, saying U.S. regulators' pause on Johnson & Johnson (NYSE:JNJ) shots, following reports it can cause blood clotting, should boost confidence in the vaccines' safety.
U.S. federal health agencies on Tuesday recommended pausing use of J&J's COVID-19 vaccine for at least a few days after six women under 50 developed rare blood clots after getting the shot.
White House COVID-19 response coordinator Jeff Zients said that U.S. regulators' quick response to the clotting reports should give Americans more confidence, not less, that any shots they receive will be safe.
"We believe that by empowering Americans with data and facts, we will strengthen the public's trust in government, and increased their confidence in the vaccines," said Zients at a press briefing on Wednesday.
Zients said the White House had taken action to speed up production and delivery schedules for Moderna (NASDAQ:MRNA) Inc and Pfizer Inc (NYSE:PFE) vaccines in a bid to offset the pause in J&J dose shipments and maintain the pace of the United States' inoculation program.
He said J&J shots have so far made up less than 5% of the more than 190 million COVID-19 vaccine doses that have been administered in the United States as of Tuesday.
"People who have vaccine appointments to receive (Pfizer and Moderna) vaccines should keep their appointments, and we will work with our partners across the country to reschedule those who are intending to get the Johnson and Johnson vaccine," U.S. Centers of Disease Control and Prevention Director Dr. Rochelle Walensky said on Wednesday.
The United States vaccine rollout is accelerating, Zients said, with providers now administering around 3.3 million shots daily on average.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.